Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research
Berthold Hocher, Christoph Reichetzeder, Markus Alter
Kidney & Blood Pressure Research (2012) Vol. 36, Iss. 1, pp. 65-84
Closed Access | Times Cited: 136

Showing 1-25 of 136 citing articles:

The pathophysiology of hypertension in patients with obesity
Vincent G. DeMarco, Annayya R. Aroor, James R. Sowers
Nature Reviews Endocrinology (2014) Vol. 10, Iss. 6, pp. 364-376
Open Access | Times Cited: 468
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, et al.
Diabetes Care (2013) Vol. 36, Iss. 11, pp. 3460-3468
Open Access | Times Cited: 280
Diabetic nephropathy: diagnosis and treatment
Daniel Fineberg, Karin Jandeleit‐Dahm, Mark E. Cooper
Nature Reviews Endocrinology (2013) Vol. 9, Iss. 12, pp. 713-723
Closed Access | Times Cited: 264
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Marcel H.A. Muskiet, Mark M. Smits, Linde M. Morsink, et al.
Nature Reviews Nephrology (2013) Vol. 10, Iss. 2, pp. 88-103
Closed Access | Times Cited: 170
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
Markus Alter, Ina M. Ott, Karoline von Websky, et al.
Kidney & Blood Pressure Research (2012) Vol. 36, Iss. 1, pp. 119-130
Open Access | Times Cited: 148
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Carolyn F. Deacon, Jens J. Holst
Expert Opinion on Pharmacotherapy (2013) Vol. 14, Iss. 15, pp. 2047-2058
Closed Access | Times Cited: 119
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Annayya R. Aroor, James R. Sowers, Guanghong Jia, et al.
AJP Heart and Circulatory Physiology (2014) Vol. 307, Iss. 4, pp. H477-H492
Open Access | Times Cited: 105
Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes
David Fitchett, Jacob A. Udell, Silvio E. Inzucchi
European Journal of Heart Failure (2016) Vol. 19, Iss. 1, pp. 43-53
Open Access | Times Cited: 98
Diabetes, hypertension, and chronic kidney disease progression: role of DPP4
Ravi Nistala, Virginia J. Savin
AJP Renal Physiology (2017) Vol. 312, Iss. 4, pp. F661-F670
Closed Access | Times Cited: 97
Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, et al.
Kidney International (2016) Vol. 90, Iss. 4, pp. 783-796
Open Access | Times Cited: 96
Do we know the true mechanism of action of the DPP‐4 inhibitors?
Emilie S. Andersen, Carolyn F. Deacon, Jens J. Holst
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 1, pp. 34-41
Closed Access | Times Cited: 95
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
Keizo Kanasaki
Clinical Science (2018) Vol. 132, Iss. 4, pp. 489-507
Open Access | Times Cited: 95
Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats
Annayya R. Aroor, James R. Sowers, Shawn B. Bender, et al.
Endocrinology (2013) Vol. 154, Iss. 7, pp. 2501-2513
Open Access | Times Cited: 98
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
Yuliya Sharkovska, Christoph Reichetzeder, Markus Alter, et al.
Journal of Hypertension (2014) Vol. 32, Iss. 11, pp. 2211-2223
Closed Access | Times Cited: 94
The DPP-4 Inhibitor Linagliptin Restores β-Cell Function and Survival in Human Isolated Islets Through GLP-1 Stabilization
Payal Shah, Amin Ardestani, Gitanjali Dharmadhikari, et al.
The Journal of Clinical Endocrinology & Metabolism (2013) Vol. 98, Iss. 7, pp. E1163-E1172
Open Access | Times Cited: 94
Concomitant Diabetes Mellitus and Heart Failure
Alessandra Dei, Gregg C. Fonarow, Mihai Gheorghiade, et al.
Current Problems in Cardiology (2014) Vol. 40, Iss. 1, pp. 7-43
Closed Access | Times Cited: 86
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy
Oleg Tsuprykov, Ryotaro Ando, Christoph Reichetzeder, et al.
Kidney International (2016) Vol. 89, Iss. 5, pp. 1049-1061
Open Access | Times Cited: 83
Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Katarina Tomović, Jelena Lazarević, Gordana Kocić, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 404-422
Open Access | Times Cited: 73
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
Ravi Nistala, Javad Habibi, Annayya R. Aroor, et al.
Obesity (2014) Vol. 22, Iss. 10, pp. 2172-2179
Open Access | Times Cited: 72
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Jixin Zhong, Quan Gong, Aditya Goud, et al.
Journal of Diabetes Research (2015) Vol. 2015, pp. 1-14
Open Access | Times Cited: 69
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism
Bo Åhrén, James E. Foley
Diabetologia (2016) Vol. 59, Iss. 5, pp. 907-917
Open Access | Times Cited: 64
More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling
Shreyasi Gupta, Utpal Sen
Pharmacological Research (2019) Vol. 147, pp. 104391-104391
Open Access | Times Cited: 55
Improved Glycemic Control in Patients with Advanced Type 2 Diabetes Mellitus Taking Urtica dioica Leaf Extract: A Randomized Double-Blind Placebo-Controlled Clinical Trial
Saeed Kianbakht, Farahnaz Khalighi‐Sigaroodi, Fataneh Hashem-Dabaghian
Clinical Laboratory (2013) Vol. 59, Iss. 09+10/2013
Closed Access | Times Cited: 69
Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction
Hye Sook Min, Jung Eun Kim, Mihwa Lee, et al.
Laboratory Investigation (2014) Vol. 94, Iss. 6, pp. 598-607
Open Access | Times Cited: 64
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
Guntram Schernthaner, Carl Erik Mogensen, G. Schernthaner
Diabetes and Vascular Disease Research (2014) Vol. 11, Iss. 5, pp. 306-323
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top